Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
P21 vs Pinealon
An educational, source-based comparison of P21 and Pinealon — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic peptide derived from cerebrolysin. Research suggests it promotes synaptic plasticity by enhancing BDNF expression and inhibiting prolyl endopeptidase, an enzyme involved in neurodegenerative processes.
- Synaptic plasticity and memory
- Neuroprotection in Alzheimer's models
- Cognitive recovery after brain injury
- • Experimental; limited human data available.
- • Not FDA-approved.
Short peptide bioregulator researched for cognition and aging.
A synthetic tripeptide (Glu-Asp-Arg) in the Khavinson short-peptide bioregulator family. Research from Russian gerontology groups proposes gene-expression modulation linked to neuronal survival and cognitive performance.
- Cognitive aging in rodent models
- Neuronal apoptosis under oxidative stress
- Circadian and neuroendocrine regulation
- • Most evidence from Russian literature; independent replication is limited.
- • Not FDA-approved.
P21 vs Pinealon — Key differences
- Class: P21 is classified as Nootropic · Neuroprotection, while Pinealon is Bioregulator · Neuroprotection.
- Primary research focus: P21 — synaptic plasticity and memory; Pinealon — cognitive aging in rodent models.
- Tag: Cognition · Neuroprotection vs Cognition · Longevity.